Helping Your Patients Find Xifaxan: A Practical Guide for Providers

When you prescribe Xifaxan (Rifaximin) for hepatic encephalopathy or IBS-D, you expect your patients to be able to fill their prescriptions without difficulty. Unfortunately, that's not always the case. Patients frequently report being told their pharmacy doesn't have Xifaxan in stock, and navigating the combination of high costs, prior authorization requirements, and inconsistent pharmacy inventory can be overwhelming for them.

This guide provides actionable steps your practice can take to minimize these barriers and keep your patients on therapy.

Current Xifaxan Availability

Xifaxan is not in a formal FDA-listed shortage as of February 2026. Salix Pharmaceuticals (Bausch Health) remains the sole manufacturer, and production appears stable. The availability challenges patients face are driven by economics and insurance logistics, not supply disruptions.

Key factors affecting availability at the pharmacy level:

• High acquisition cost: $1,600–$2,200 for a 30-day supply (550 mg, 60 tablets) means pharmacies may not maintain standing stock
• Sole-source manufacturing: No generic Rifaximin is available; exclusivity extends through 2028-2029
• Prior authorization requirements: Most commercial and Medicare Part D plans require PA, often with step therapy
• Specialty tier placement: High copays discourage some patients from filling prescriptions even when approved

Why Patients Can't Find Xifaxan

Understanding the patient experience helps you address their concerns:

The Pharmacy Stocking Problem

A typical retail pharmacy serves a broad patient population and stocks medications based on local demand. Because Xifaxan is expensive and prescribed primarily by specialists, many retail pharmacies don't carry it as a standard shelf item. When a patient brings in a prescription, the pharmacy may need to order it — a process that takes 1-3 business days.

For patients with hepatic encephalopathy, who take Xifaxan daily, even a short gap can have clinical consequences. For IBS-D patients starting a 14-day course, delays can be demoralizing when they're already symptomatic.

The Insurance Approval Cycle

Even when a pharmacy has Xifaxan in stock, insurance approval delays can prevent dispensing. The typical workflow looks like this:

1. Provider sends e-prescription to pharmacy
2. Pharmacy submits to insurance → claim rejects (PA required)
3. Pharmacy notifies patient → patient contacts provider
4. Provider submits PA → insurer reviews (24-72 hours)
5. PA approved → pharmacy fills prescription (if in stock)

This process can take 3-7 days, during which the patient goes without medication. Proactive PA submission can eliminate much of this delay.

What Providers Can Do: 5 Key Steps

Step 1: Submit Prior Authorization at the Point of Prescribing

Don't wait for the pharmacy to trigger a PA rejection. Submit prior authorization paperwork at the same time you write the prescription. Include all supporting documentation upfront:

• Confirmed diagnosis (ICD-10 codes)
• Prior treatment history (especially Lactulose for HE — most plans require step therapy documentation)
• Relevant lab work (ammonia levels, liver function tests for HE patients)
• Clinical rationale for Xifaxan specifically

Many EHR systems support electronic prior authorization (ePA), which can reduce turnaround to hours instead of days.

Step 2: Direct Prescriptions to Pharmacies With Stock

Before sending an e-prescription, check whether the target pharmacy has Xifaxan in stock. Medfinder for Providers allows you to search for nearby pharmacies with confirmed Xifaxan inventory. This simple step prevents the common scenario where a patient arrives at a pharmacy only to be told the drug needs to be ordered.

Step 3: Establish Specialty Pharmacy Relationships

Identify one or two specialty pharmacies in your area that reliably stock Xifaxan and build a working relationship with them. Benefits include:

• Consistent inventory of Xifaxan and other GI specialty medications
• Staff experienced in handling complex PA processes
• Proactive patient outreach for refills and copay assistance enrollment
• Integration with manufacturer savings programs

Ask your Salix/Bausch Health representative for a list of preferred specialty pharmacies in your area.

Step 4: Enroll Patients in Savings Programs

Cost is a significant barrier, even for insured patients. Ensure your staff knows about these programs:

• Xifaxan Instant Copay Savings Card: $0 copay for eligible commercially insured patients. Download at xifaxan.copaysavingsprogram.com or call 1-866-XIFAXAN. Not valid for government insurance.
• Patient Access Network (PAN) Foundation: Copay assistance for eligible patients, including those on Medicare
• Bausch Health Patient Assistance Program: Free medication for qualifying uninsured/underinsured patients

For a comprehensive cost-saving resource, see our guide on helping patients save money on Xifaxan.

Step 5: Recommend Mail-Order Pharmacy for Ongoing Therapy

For patients on chronic Xifaxan therapy (especially HE patients taking it twice daily on an ongoing basis), mail-order pharmacy eliminates the recurring challenge of finding local stock. Most insurance plans offer 90-day mail-order supplies, often at a lower per-dose copay. Help patients set up automatic refills to prevent gaps.

When to Consider Alternatives

If Xifaxan access is significantly delayed and the patient's clinical situation requires immediate treatment, consider these alternatives:

Hepatic Encephalopathy:

• Lactulose — First-line therapy; available generically at $10-$30/month; many patients are already on it. Ensure adequate dosing (titrate to 2-3 soft stools/day).
• Neomycin — Alternative antibiotic; suitable for short-term use only due to nephrotoxicity and ototoxicity risks.

IBS-D:

• Eluxadoline (Viberzi) — FDA-approved; contraindicated without gallbladder; Schedule IV
• Alosetron — For women with severe IBS-D only; restricted prescribing program
• Dietary modification — Low-FODMAP diet as adjunctive therapy

For clinical comparisons, review our article on alternatives to Xifaxan.

Workflow Tips for Your Practice

Incorporate these workflow optimizations to reduce Xifaxan access issues:

• Create a Xifaxan prescribing checklist for your front-desk or nursing staff that includes PA submission, savings card enrollment, and pharmacy stock verification
• Flag Xifaxan patients in your EHR for proactive refill reminders — especially HE patients where treatment gaps carry clinical risk
• Assign a staff member to handle specialty medication PAs and patient assistance program applications
• Use Medfinder as a standard tool when prescribing any medication with known availability challenges — visit medfinder.com/providers

Final Thoughts

Xifaxan access challenges in 2026 are driven by cost, insurance complexity, and limited pharmacy stocking — not a supply shortage. By proactively managing prior authorizations, directing prescriptions to pharmacies with confirmed stock, and connecting patients with savings programs, your practice can significantly reduce treatment disruptions.

Tools like Medfinder for Providers make it easier to verify pharmacy inventory before prescribing. Combined with specialty pharmacy partnerships and patient education, these strategies help ensure your patients stay on therapy.

For additional context on the Xifaxan supply landscape, see our provider briefing on Xifaxan availability.